Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

By sjmartinez • September 22, 2022

Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2022 Sep 22:annrheumdis-2022-222259. doi: 10.1136/ard-2022-222259. Epub ahead of print. PMID: 36137735.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology, Therapeutics

Researcher Attitudes towards Hypothetical Genetic Research with Navajo People: Results from an Online Survey

Sherman CA, Garrison NA, Claw KG. Researcher Attitudes towards Hypothetical Genetic Research with Navajo People: Results from an Online Survey. HGG Adv. 2025 Sep 27:100524.[...]

Association of BMI and Cognitive Performance in the Diabetes Prevention Program Outcomes Study

Luchsinger JA, Pan Q, Knowler WC, Munshi M, Watson K, Gadde KM, Schlögl M, Carmichael OT; DPP Research Group. Association of BMI and Cognitive Performance[...]

Developing and Evaluating a Natural Language Processing Algorithm to Detect Insulin Pump and Continuous Glucose Monitor Use in Electronic Health Records of Patients with Type 1 Diabetes

Everett E, Tiu RA, Zhu B, Feng J, Jackson N, Graham J, Ipp E, Mathioudakis N, Bui AAT, Moin T. Developing and Evaluating a Natural[...]